A 73-Year-Old Man with Advanced Renal Cell Carcinoma - Episode 4

Cabozantinib, Nivolumab, and Ipilimumab: Rationale for Use

Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.